EP0196415A2

EP0196415A2 - Trichostatins A and C as antitumour drugs

Info

Publication number: EP0196415A2
Application number: EP86101047A
Authority: EP
Inventors: Teruhiko Beppu; Yasushi Iwamoto; Minoru Yoshida
Original assignee: Individual
Current assignee: Individual
Priority date: 1985-01-30
Filing date: 1986-01-27
Publication date: 1986-10-08
Anticipated expiration: 2006-01-27
Also published as: EP0196415B1; JPH0466453B2; JPS61176523A; DE3682091D1; US4690918A; EP0196415A3

Abstract

Use of trichostatin A and/or trichostatin C for the manufacture of an antitumour drug.

Description

The present invention relates to an antitumour drug. More particularly, the present invention relates to a novel use of a compound of the formula:
wherein X is a hydrogen atom or a group of the formula:
as an antitumour drug which inhibits proliferation of tumour cells in human or animal by inducing the differentiation of the tumour cells.
Tumours are generally classified into solid tumours and liquid tumours (hematopoietic organs). Treatments of tumours are generally classified into surgical therapy, drug therapy and radiation therapy.
For the treatment of a solid tumour such as gastric cancer, surgical therapy or a combination of surgical therapy and radiation therapy has been traditionally employed as the first choice. Once the metastasis is observed, drug therapy is used as a secondary or tertiary method of treatment. On the other hand, in the case of a liquid tumour such as leukemia, drug therapy is applied immediately after the positive diagnosis.
Tumours are not a single type of diseases and show different sensitivities to various therapeutic methods. As mentioned above, however, the significance of drug therapy is extremely great in any type of tumours.
Such drug therapy includes chemotherapy, immunotherapy and hormonetherapy. Among them, the most important therapyl.at present is chemotherapy which inhibits the metabolism of tumour cells by a direct action to tumour cells, or which inhibits proliferation of tumour cells by suppressing the DNA synthesis.
At least some tumour cells are considered to be undifferentiated cells wherein the differentiation is interrupted for some reasons. Heretofore, some studies have been made to differentiate such tumour cells to convert the undifferentiated cells to functional cells i.e. terminal cells. In general, terminal cells do not proliferate, and therefore a drug which is capable of inducing the differentiation of tumour cells, can be an effective antitumour agent. For instance, there have been known some substances which are capable of inducing the differentiation of Friend leukemia cells as one type of experimental models. For instance, low molecular polar compounds such as dimethylsulfoxide (DMSO) and hexamethylenebisacetamide (HMBA) which are believed to act on the cell membranes of tumour cells to exhibit their effectiveness, have strong activities for inducing the differentiation. However, such activities are obtainable only at a high concentration of from some mM to some hundreds mM (Proceedings of the National Academy of Sciences of the U.S.A., vol. 73, No. 3, p 862-866, 1976, published by the National Academy of Sciences of the United States of America). Therefore, it is difficult to use them for practical applications. On the other hand, some carcinostatic antibiotic substances such as bleomycin and mitomycin C which are believed to act on DNA, have been reported to have activities for inducing the differentiation of tumour cells at low concentrations. However, such activities are generally weak (Cancer Research, vol. 38, p 841-849, 1978, published by the Official Organ of the American Association for Cancer Research, Inc.). In the case of Friend leukemia cells, there is a general tendency (although there are some variations depending upon the particular cell strains used) that substances acting on the cell membranes require high concentration although their differentiation-inducing activities are strong, and substances acting on DNA are weak in their activities although they show the activities at a low concentration.
Under the circumstances, it has been strongly desired to develop an antitumour drug which has high carcinostatic activities and which has high selective toxicity against tumour cells.
Accordingly, it is an object of the present invention to provide an antitumour drug which not only exhibits strong carcinostatic activities at a low concentration but also exhibits extremely high selective toxicity to cancer cells, i.e. an extremely strong and highly safe antitumour drug.
The present invention is based on a discovery that the compounds of the above-mentioned formula I have such excellent antitumour activities.
The compounds of the formula I are known compounds. Namely, the compound wherein X is a'hydrogen atom is trichostatin A (the Journal of Antibiotics, vol. 29, No. 1, p 1-6, 1976, published by Japan Antibiotics Research Association), and the compound wherein X is the group of the formula II is trichostatin C (the Journal of Antibiotics, vol. 31, No. 10, p 939-944, 1978). Both compounds have been known to have antifungal activities, but their antitumour activities have not been known.
Thus, the present invention provides use of trichostatin A and/or trichostatin C for the manufacture of an antitumour drug.
Now, the present invention will be described in detail with reference to the preferred embodiments.
The compounds of the present invention may be in the form of pharmaceutically acceptable salts. As such pharmaceutically acceptable salts, any salts may be used so long as they do not adversely affect the desired pharmacological effects of the compounds. The selection and the production thereof can readily be made by those skilled in the art. For instance, as a pharmaceutically acceptable salt, an alkali metal salt such as a sodium salt or a potassium salt, an alkaline earth metal salt such as a calcium salt or a magnesium salt, a salt with an organic base such as an ammonium salt, or a salt with an organic base such as a triethylamine salt or an ethanolamine salt, may be employed.
The carcinostatic activities of the antitumour drugs of the present invention were determined by using Friend leukemia cells (see Test Example 1 given hereinafter).
Friend leukemia cells are cells which are commonly used as one of experimental cancer models for the researches on the inducement of the differentiation of tumour cells (Annual Review of Biochemistry, vol. 47, p 419-448, 1978, published by Annual Review Inc., U.S.A.). They are tumour cells of a mouse, which proliferate with the differentiation of the proerythroblasts being suspended by the infection with Friend virus. These tumour cells are undifferentiated proerythroblast cells, and therefore do not produce hemoglobin. However, once they are differentiated to red blood cells, such cells produce hemoglobin. Therefore, the degree of differentiation can be evaluated on the basis of the hemoglobin production.
Various substances have been known as substances for inducing the differentiation of tumour cells. For instance, the above-mentionied dimethylsulfoxide (DMSO) and hexamethylenebisacetamide (HMBA) may be mentioned.
The fact that the antitumour drugs of the present invention exhibit strong activities for inducing the differentiation of tumour cells at an extremely low concentration, was confirmed also with respect to erythroleukemia cells derived from a mouse like Friend leukemia cells, formed by the infection with Rausher virus (see Test Example 2 given hereinafter). As a substance of which the activities for inducing the differentiation has been confirmed by such erythroleukemia cells, 12-0-tetradecanoylphorbol-13-acetate (TPA), dimethylsulfoxide (DMSO) of hexamethylenebis-acetamide (HMBA) has been known.
The fact that the antitumour drugs of the present invention have extremely high selective toxicity against tumour cells, has been confirmed by comparing the activities against the tumour cells formed by the infection with tumour virus SV 40 and against the normal parent cells (see Test Example 3 given hereinafter).
The antitumour drugs of the present invention may be administered orally or non-orally. In the case of oral administration, they may be administered in the form of soft and hard capsules, tablets, granules, powders or the like. In the case of non-oral administration, they may be administered in the form of injection solutions, drip infusion formulations, or formulations such as suppositories whereby continuous membrane absorption can be maintained in the form of solid or viscous liquid of suspension. The selection of the method for preparation of these formulations and the vehicles, disintegrators or suspending agents, can readily be made by those skilled in the art. The antitumour drugs of the present invention may contain a further substance having carcinostatic activities, in addition to the compounds of the formula I or their pharmaceutically acceptable salts.
The amount of the active ingredients in the antitumour composition of the present invention may vary depending upon the formulation, but is usually from 0.1 to 50% by weight irrespective of the manner of administration.
The dose is determined taking into consideration the age, sex and symptom of disease of the patient, the desired therapeutic effect, the period for administration, etc. However, preferably a daily dose of the active ingredient is from 0.05 to 100 mg for an adult.
Now, the present invention will be described in further detail with reference to Examples and Test Examples. However, it should be understood that the present invention is by no means restricted by these specific Examples.

EXAMPLE (Formulation Example)

5 mg of trichostatin A as an active ingredient of the antitumour drug of the present invention, was dissolved in a mixture comprising 1 g of purified sesame oil and 100 mg of aluminum stearate gel. The solution thus obtained was introduced in an amount of 0.5 ml each into capsules to obtain capsules for oral administration. TEST EXAMPLE 1 (Differentiation-inducing effects on Friend leukemia cells)

(1) Test Method -

Culture medium used: 9.4 g of Eagle MEM No. 1 culture medium (manufactured by Nissui Seiyaku K.K.), 0.3 g of L-glutamine and 2 g of sodium bicarbonate were dissolved in 1 liter of distilled water, and then fetal calf serum (manufactured by Armour Pharmaceutical Co.) was added in an amount such that the final concentration would be 12% by volume.
Into a cluster dish with 24 perforations made of Coster Co., U.S.A., 0.5 ml of the above culture medium, 1 x 10⁵ cells/ml of Friend leukemia cells DS 19 strain (obtained from the Institute of Applied Microbiology of Tokyo University) and the test compound in a concentration as identified in Table 1, were introduced, and the cells were cultured in a 5% carbon dioxide gas incubator at 37°C. Five days later, the cells were collected by centrifugal separation, and dyed with benzidine. The cells which underwent differentiation and became red blood cells, produce hemoglobin, and they can be counted under microscopic observation by using a hemocytometer in accordance with the Orkin's benzidine dyeing method. The ratio of the number of benzidine positive cells to the total number of cells thus counted was obtained as the differentiation-inducing rate.

(2) Test results

Hexamethylenebisacetamide (HMBA) which has been known to exhibit the strongest differentiation-inducing activities against Friend leukemia cells DS 19 strain, was tested at the same time, whereby the differentiation-inducing rate was 75% at a concentration of 4 mM. As calculated from the data shown in Table 1, the amount required to obtain the same differentiation-inducing rate, is about 1/310,000 (as calculated from 0.013 µM) in the case of trichostatin A, or about 1/6,200 (as calculated from 0.65 pM) in the case of trichostatin C. Thus, the antitumour drugs of the present invention have remarkably superior activities for inducing the differentiation of tumour cells.

TEST EXAMPLE 2 (Differentiation-inducing effects on Rausher virus infected leukemia cells)

(1) Test method

Culture medium used: 10.2 g of RPM I 1640 No. 2 culture medium (manufactured by Nissui Seiyaku K.K.), 0.3 g of L-glutamine and 2 g of sodium bicarbonate were dissolved in 1 liter of distilled water, and then fetal calf serum (manufactured by Armour Pharmaceutical Co., U.S.A.) was added in an amount such that the final concentration would be 12% by volume.
In the same manner as in Test Example 1, the differentiation-inducing rate against erythroleukemia cells RV-133 derived from a mouse (obtained from Institute of Applied Microbiology of Tokyo University) was measured.

(2) Test results

The above data indicate that the active ingredients of the antitumour drugs of the present invention exhibit strong differentiation-inducing activities at an extremely low concentration at a level of less than 1 mg/ml also against erythroleukemia cells formed by the infection with Rausher virus, as in the case against Friend leukemia cells. _/

TEST EXAMPLE 3 (Selective toxicity against tumour cells)

Toxicity of the active ingredients of the antitumour drugs of the present invention was compared as between against normal fibroblast cells taken from the kidney of a C3H/He mouse (C3H-2K) (obtained from the Institute of Medical Science of Tokyo University) and against tumour cells formed by the infection of the same cells with tumour virus SV40 (SV40-C3H-2K) (obtained from the same Institute).

(1) Test method

Culture medium used: same as used in Test Example 1

Into cluster dish with 24 perforations made by Costar Co., U.S.A., 0.9 ml of the above culture medium and 0.1 ml of a cell suspension prepared to contain 1 x 10⁶ cells/ml were introduced to bring the cell density to a level of 1 x 10⁵ cells/ml. The cells were cultured in a 5% carbon dioxide gas incubator at 37°C overnight. Then, after replacing the culture medium with a fresh medium, a methanol solution of the test compound was added in the concentration as identified in Table 3, and the culturing was continued. Upon expiration of 72 hours from the addition of the test compound, the culture medium was removed, and the deposited cells were suspended by trypsin treatment. The dead cells were dyed by a trypan blue dyeing method, and the number of survived cells were counted on a red hemocytometer. The cell-growth inhibiting rate (%) calculated by the following formula was used as a reference for the evaluation of the selective toxicity.

(2) Test results

From the above data, it is evident that the difference in the toxicity of the active ingredients of the antitumour drugs of the present invention against the normal cells and against the tumour cells is extremely large, and thus proves that the active ingredients have remarkably high selective toxicity against the tumour cells.
As described in the foregoing, the present invention provides antitumour drugs which not only exhibit strong carcinostatic activities at an extremely low concentration but also have extremely high selective toxicity against tumour cells, i.e. extremely strong and highly safe antitumour agents.

Claims

1. Use of trichostatin A and/or trichostatin C for the manufacture of an antitumour drug.

2. The use according to Claim 1, wherein the antitumour drug is a drug which induces the differentiation of tumour cells in human or animal.

3. The use according to Claim 1, wherein the antitumour drug is a drug which inhibits proliferation of tumour cells.

4. Use of trichostatin A for the manufacture of a drug for inhibiting proliferation of tumour cells in human or animal.

5. Use of trichostatin C for the manufacture of a drug for inhibiting proliferation of tumour cells in humand or animal.